Inovio Pharmaceuticals (NASDAQ:INO) : Inovio Pharmaceuticals (NASDAQ:INO) had a healthy money flow of $0.72 million into the stock during the Wednesdays trading session. The value of bullish trades on upticks was $3.37 million, whereas, investors only sold shares worth $2.65 million on downticks. The stock closed the day with an up-down ratio of 1.27.The money flow in the block trades to the tune of $0.6 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $0.71 million worth of transactions were on upticks. A paltry $0.11 million worth of block trade transactions on downticks shows that the investors are reluctant to sell the stock down. The total up-down ratio of the upticks vs the downticks in block trades was 6.5. Inovio Pharmaceuticals (NASDAQ:INO) stock slid $0.03 intraday and traded at 9.18, a change of -0.33% over previous days close. However, for the week, the company shares are 0.11% compared to previous weeks close.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Inovio Pharmaceuticals, Inc., Benito Simon X had sold 6,250 shares worth of $64,813 in a transaction dated May 18, 2016. In this transaction, 6,250 shares were sold at $10.37 per share. Currently the company Insiders own 9.9% of Inovio Pharmaceuticals shares according to the proxy statements. Institutional Investors own 27.22% of Inovio Pharmaceuticals shares.
The company shares have rallied 13.15% from its 1 Year high price. On Apr 28, 2016, the shares registered one year high at $11.69 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $10.42 and the 200 Day Moving Average price is recorded at $8.16. Inovio Pharmaceuticals (NASDAQ:INO): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $9.59 and $9.04 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $9.60. The buying momentum continued till the end and the stock did not give up its gains. It closed at $9.43, notching a gain of 2.39% for the day. The total traded volume was 2,260,106 . The stock had closed at $9.21 on the previous day.
Inovio Pharmaceuticals, Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31, 2014, Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza and Ebola. With its immunotherapy platform consisting of SynCon products, as well as its CELLECTRA electroporation delivery technology, Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovios immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.